Pharmaceutical company focused on identifying and developing clinical stage compounds for treatment of rare diseases and other diseases with unmet medical needs Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) has entered into a partnership with Calvert Labs to design and execute explanatory studies linked to Tryp’s psilocybin-for-neuropsychiatric disorder program.
Calvert Labs is a preclinical contact research organization (CRO) which offers a wide range of lead identification, lead optimization and clinical services.
According to the partnership agreement, the research will focus on generating toxicology and blood exposure level data for Tryp’s proprietary psilocybin based formulation,TRP-8803, while strengthening Tryp’s intellectual property portfolio for the drug product.
Completion of this research will also provide regulatory support for Tryp’s novel methods for the formulation, delivery and dosing of its products in future clinical trials.
“This partnership marks an important milestone for us as we continue to build momentum towards our Phase 2b clinical studies with our proprietary TRP-8803 formulation. Calvert Labs and Gad Consulting Services are ideally suited to perform these important studies given their international expertise in toxicology. Our work with these organizations and with Altasciences will accelerate our time into the clinic with TRP-8803,” said Tryp’s chief science officer, Jim Gilligan.
